These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2506942)

  • 1. Prolactin response to dopamine and valproate administration in breast cancer patients.
    Stalldecker GB; Pigni J; Fuentes AM; Vegh I
    Biomed Pharmacother; 1989; 43(4):301-6. PubMed ID: 2506942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
    Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
    Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activation of gamma-aminobutyric acid-system blunts prolactin response to mechanical breast stimulation in puerperal women.
    Melis GB; Fruzzetti F; Paoletti AM; Mais V; Kemeny A; Strigini F; Boldrini A; Fioretti P
    J Clin Endocrinol Metab; 1984 Jan; 58(1):201-5. PubMed ID: 6417154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the GABAergic drug, sodium valproate, on the prolactin release evoked by pharmacological stimuli in normal women.
    Melis GB; Fruzzetti F; Paoletti AM; Mais V; Beneventi F; Trimarchi G; Fioretti P
    Clin Endocrinol (Oxf); 1984 Mar; 20(3):245-52. PubMed ID: 6426828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism.
    Ho KY; Smythe GA; Duncan M; Lazarus L
    J Clin Endocrinol Metab; 1984 Jan; 58(1):128-33. PubMed ID: 6689678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GABAergic control of prolactin release is not affected by insulin-dependent diabetes mellitus: evidence from studies with sodium valproate.
    Coiro V; Davoli C; Volpi R; Sorini E; Voltini E; Rossi G; Delsignore R; Gnudi A; Chiodera P
    Acta Diabetol Lat; 1986; 23(1):51-5. PubMed ID: 3012924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of thyrotropin and prolactin secretion by dopamine in man.
    Massara F; Camanni F; Vergano V; Belforte L; Molinatti GM
    J Endocrinol Invest; 1978 Jan; 1(1):25-30. PubMed ID: 573767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VIP removes the inhibition of prolactin secretion induced by dopamine in patients with prolactinoma].
    Tater D; Charpentier G; Besson G; Rosselin G; Bercovici JP
    C R Seances Acad Sci III; 1983; 297(6):331-4. PubMed ID: 6420004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.
    Nicoletti I; Filipponi P; Sfrappini M; Fedeli L; Petrelli S; Gregorini G; Santeusanio F; Brunetti P
    Horm Res; 1984; 19(3):158-70. PubMed ID: 6425187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
    Mandalà M; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Confalonieri G; Malugani F; Moro C; Fumagalli G; Giani L; Tancini G
    Tumori; 1999; 85(6):494-7. PubMed ID: 10774572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia.
    Webb CB; Thominet JL; Barowsky H; Berelowitz M; Frohman LA
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1089-93. PubMed ID: 6841551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
    Serri O; Kuchel O; Buu NT; Somma M
    J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of trh and dopaminergic mechanisms in the regulation of stimulated prolactin release in man.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1985 Jul; 23(1):7-16. PubMed ID: 3928213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased dopaminergic activity inhibits basal and metoclopramide-stimulated prolactin and thyrotropin secretion.
    Agner T; Hagen C; Andersen AN; Djursing H
    J Clin Endocrinol Metab; 1986 Apr; 62(4):778-82. PubMed ID: 3949956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
    Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
    Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects.
    Melis GB; Paoletti AM; Mais V; Mastrapasqua NM; Strigini F; Fruzzetti F; Guarnieri G; Gambacciani M; Fioretti P
    J Clin Endocrinol Metab; 1982 Mar; 54(3):485-9. PubMed ID: 6799535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal polypeptide and dopamine: effect on prolactin secretion in normal women and patients with microprolactinomas.
    Conti A; Togni E; Travaglini P; Muratori M; Faglia G
    Neuroendocrinology; 1987 Sep; 46(3):241-5. PubMed ID: 3658111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
    Hanew K; Sato S; Sasaki A; Goh M; Shimizu Y; Murakami O; Yoshinaga K
    Endocrinol Jpn; 1985 Dec; 32(6):811-7. PubMed ID: 3938732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic studies of highly purified human prolactin in normal human subjects.
    Molitch ME; Raiti S; Baumann G; Belknap S; Reichlin S
    J Clin Endocrinol Metab; 1987 Aug; 65(2):299-304. PubMed ID: 3597709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.